Profile of saxagliptin in the treatment of type 2 diabetes: Focus on Japanese patients

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 547-558

  Konya, Hiroyuki ^a   Yano, Yuzo ^a   Matsutani, Satoshi ^a   Tsunoda, Taku ^b   Ikawa, Takashi ^b   Kusunoki, Yoshiki ^b   Matsuo, Toshihiro ^b   Miuchi, Masayuki ^b   Katsuno, Tomoyuki ^c   Hamaguchi, Tomoya ^d   Miyagawa, Jun Ichiro ^b   Namba, Mitsuyoshi ^b  

^a Department of Internal Medicine   (Japan)

^b Kawasaki Medical School   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Itami City Hospital   (Japan)

Author keywords

Dipeptidyl peptidase 4; Efficacy; Incretin hormones; Japan; Patient acceptability; Safety; Saxagliptin; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; CASE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JAPAN; JAPANESE (PEOPLE); MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; TREATMENT DURATION; TREATMENT PLANNING; WEIGHT GAIN;

EID: 84904391201     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S46076     Document Type: Review

References (52)

1. International Diabetes Association. The global burden, diabetes and impaired glucose tolerance. Available from: https: //www.idf.org/sites/default/files/The_Global_Burden.pdf. Accessed June 9, 2014.
2. International Diabetes Association. The global burden, mortality. IDF Diabetes Atlas. 6th ed. Available from: http: //www.idf.org/diabetesatlas/global-burden. Accessed June 9, 2014.
3. Holz GG, Kühtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature. 1993; 361(6410): 362-365.
4. Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007; 107 Suppl: S6-S9.
5. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004; 53 Suppl 3: S190-S196.
6. Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl. 2008; 159: 8-14.
7. Banerjee M, Younis N, Soran H. Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother. 2009; 10(16): 2745-2757.
8. Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med. 2009; 121(6): 70-100.
9. Namba M, Katsuno T, Kusunoki Y, Matsuo T, Miuchi M, Miyagawa J. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol. 2013; 17(1): 10-15.
10. Konya H, Tsunoda T, Kamitani M, et al. Add-on effect of sitagliptin in an obese type 2 diabetic patient with glimepiride and metformin on blood glucose control and incretin response. J Diabetes Invest. 2012; 3 Suppl 1: S206.
11. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J. 2013; 60(6): 733-742.
12. Kusunoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J. 2013; 60(4): 431-439.
13. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009; 23(4): 479-486.
14. Onglyza® (saxagliptin). Full prescribing information. Princeton, NJ, USA: Wilmington, DE. Bristol-Myers Sqibb/AstraZeneca Pharmaceuticals LP; 2009.
15. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009; 25(10): 2401-2411.
16. DeFronzo R, Hissa MN, Garber AJ, et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes. 2009; 58 Suppl 1: 547P.
17. Chacra AR, Tan GH, Ravichandran S, List J, Chen R; CV181-040 Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011; 8(2): 150-159.
18. Hollander PL, Li J, Frederich R, Allen E, Chen R; CV181-013 Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011; 8(2): 125-135.
19. Pfützner A, Paz-Pacheco E, Allen E, Frederich B, Chen R; for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011; 13(6): 567-576.
20. Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012; 4(1): 36.
21. Poolsup N, Suksomboon N, Setwiwattanakul W. Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. ISRN Endocrinol. 2012; 2012: 798146.
22. Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011; 154(10): 672-679.
23. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16(5): 410-417.
24. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003; 46(1): 3-19.
25. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care. 1997; 20(10): 1562-1568.
26. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2002; 44(8): 929-945.
27. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004; 66 Suppl 1: S37-S43.
28. Fukuda-Akita E, Okita K, Okauchi Y, et al. Impaired early insulin secretion in Japanese type 2 diabetes with metabolic syndrome. Diabetes Res Clin Pract. 2008; 79(3): 482-489.
29. Mandavilli A, Cyranoski D. News feature: Asia's big problem. Nat Med. 2004; 10(4): 325-327.
30. Iwahashi H, Okauchi Y, Ryo M, et al. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Invest. 2012; 3(3): 271-275.
31. Iwao T, Sakai K, Ando E. Relative contribution of insulin secretion and sensitivity at different stages of glucose tolerance: non-obese versus obese Japanese subjects. Intern Med. 2014; 53(5): 383-390.
32. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest. 2010; 1(1-2): 9-23.
33. Chan CN, Malik V, Jia W, et al. Diabetes in Asia epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301(20): 2129-2140.
34. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012; 46(11): 1453-1469.
35. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013; 56(4): 696-708.
36. Aso Y, Ozeki N, Terasawa T, et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res. 2012; 159(1): 25-31.
37. Horikawa C, Yoshimura Y, Kamada C, et al. Dietary intake in Japanese patients with type 2 diabetes: analysis from Japan Diabetes Complications Study. J Diabetes Investig. 2014; 5(2): 176-187.
38. Wong MC, Wang HH, Kwan MW, et al. Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review. PLoS One. 2014; 9(3): e90963.
39. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002; 18 Suppl 3: S9-S13.
40. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract. 2006; 73(2): 198-204.
41. Kozawa J, Kitamura T, Nishizawa H, et al. Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance. J Diabetes Invest. 2013; 4(2): 190-194.
42. Kadowaki T. Efficacy and safety of a novel DPP-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus-the results of clinical trials in Japan. Jap Pharmacol Ther. 2013; 41(8): 803-815.
43. Onglyza® (saxagliptin). A Phase II multiple dose study in Japanese patients. Summary of Product Characteristics. Tokyo, Japan: Kyowa Hakko Kirin Co, Ltd; 2009. Available from http: //www.kksmile.com/druginfo/interv/ong_in.pdf. Accessed June 30, 2014.
44. Onglyza® (saxagliptin). A Phase III long-term monotherapy trial in Japanese patients. Summary of Product Characteristics. Tokyo, Japan: Kyowa Hakko Kirin Co, Ltd; 2011. Available from http: //www.kksmile.com/druginfo/interv/ong_in.pdf. Accessed June 30, 2014.
45. Onglyza® (saxagliptin). A phase III long-term combination therapy trial in Japanese patients. Summary of Product Characteristics. Tokyo, Japan: Kyowa Hakko Kirin Co, Ltd; 2012. Available from http: //www.kksmile.com/druginfo/interv/ong_in.pdf. Accessed June 30, 2014.
46. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010; 122(3): 16-27.
47. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev. 2013; 29(5): 417-426.
48. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14): 1317-1326.
49. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14): 1327-1335.
50. Schernthaner G, Sattar N. Lessons from SAVOR and EXAMINE: some important answers, but many open questions. J Diabetes Complications. February 26, 2014. [Epub ahead of print.]
51. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013; 125(3): 7-20.
52. Ou X, O'Leary HA, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood. 2013; 122(2): 161-169.